NVDA+0.84%AAPL−2.51%GOOGL−1.17%MSFT−2.04%AMZN−0.15%TSM+2.85%SPCX−1.20%AVGO+0.21%
StockVS

NASDAQ · Diagnostics & Research · USD

Mainz Biomed NV (MYNZ) Stock Analysis

Mainz Biomed NV (MYNZ) is a Diagnostics & Research stock listed on NASDAQ and quoted in US Dollar.

MYNZ

$0.33

−$0.01 (−3.80%)

Last trade May 11, 2026

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare MYNZ with… →

MYNZ Key Statistics

As of May 11, 2026
Trading
Open
$0.35
Previous Close
$0.35
Day's Range
0.32–0.36
52-Week Range
0.55–5.34
Volume
354.11K
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
0.32
Valuation
Market Cap
$10.56M
P/E Ratio
unprofitable
P/S ratioMarket value divided by annual revenue. Useful for companies that are not yet profitable, where a P/E cannot be calculated.
16.01
EPS (ttm)Profit attributable to each share over the last twelve months.
−5.28
Financials (FY)
Profit marginThe share of revenue left as profit after all costs and taxes.
0.00%
1-Year Return
−86.37%
Dividend and dates
Avg Volume
625.47K

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

MYNZ Stock Return by Calendar Year

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)−70.18%
2025−76.02%

As of May 11, 2026.

MYNZ Valuation vs Diagnostics & Research Median

Median of 49 stocks
MetricMYNZDiagnostics & Research medianvs median
P/S ratio16.014.993.2x the median
Profit margin0.00%0.00%0.0 pts above

Medians across 49 Diagnostics & Research stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of September 4, 2026.

Analysis

Data-derived

Company Overview

Mainz Biomed NV (MYNZ) carries a market capitalisation of $10.56M. It is classified in the Diagnostics & Research industry, within the Healthcare sector. The company reports 19 employees.

MYNZ last closed at $0.33 on May 11, 2026. That is −$0.01 (−3.80%) against the previous close. The 52-week range on file runs from $0.55 to $5.34.

Financial Health

Trailing twelve-month revenue on file is $659.94K. The reported profit margin is 0%. Earnings per share on a trailing basis come to −5.28.

Valuation Assessment

No trailing P/E applies: the last reported earnings figure is negative. Measured against sales, the shares trade at 16.01 times revenue. On price-to-sales that is 3.2 times the Diagnostics & Research median of 4.99. The medians here are taken across 49 Diagnostics & Research companies that report the metric.

The trailing one-year price return is −86.37%. The reported beta is 0.32. Daily returns over the trailing 1 year annualize to a volatility of 96.97%.

Growth & Income

The record shows no dividend for MYNZ.

So far in 2026 the price is −70.18%. The record holds one complete calendar year, 2025, which returned −76.02%.

Peer Comparison

Mainz Biomed NV (MYNZ) operates in the Diagnostics & Research industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
Mainz Biomed NV MYNZ $10.56M —
Thermo Fisher Scientific Inc. TMO $226.94B 33.0
Danaher Corporation DHR $145.98B 37.0
Natera, Inc. NTRA $47.31B —

The Diagnostics & Research industry average P/E ratio is 33.1x. Mainz Biomed NV has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each nightly rebuild. Informational only, not financial advice. As of May 11, 2026.

Related Diagnostics & Research Stocks

TMO

Thermo Fisher Scientific Inc.

$226.94B

 DHR

Danaher Corporation

$145.98B

 NTRA

Natera, Inc.

$47.31B

 IQV

IQVIA Holdings Inc.

$44.07B

 A

Agilent Technologies, Inc.

$42.54B

 IDXX

IDEXX Laboratories, Inc.

$42.18B
View all Diagnostics & Research stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.02T

 JNJ

Johnson & Johnson

$663.28B

 ABBV

AbbVie Inc.

$453.19B

 MRK

Merck & Co., Inc.

$370.89B

 UNH

UnitedHealth Group Incorporated

$356.47B
View all Healthcare stocks →

About Mainz Biomed NV

Mainz Biomed N.V. develops and sells in-vitro diagnostic (IVD) tests for the early detection of cancer in the United States and Europe. It offers ColoAlert, a colorectal cancer diagnostic molecular genetic stool test. The company also develops PancAlert, a stool-based screening test for the detection of pancreatic cancer. In addition, it operates a clinical diagnostic laboratory; and distributes its IVD kits to third-party laboratories. The company has a collaboration agreement with Thermo Fisher Scientific Inc. for the development and commercialization of colorectal cancer screening product. Mainz Biomed N.V. was founded in 2008 and is based in Mainz, Germany.

Visit website →